Oxford Nanopore falls despite underlying loss beating expectations

Oxford Nanopore Technologies PLC shares fell 2.9% despite the company reporting strong H1 2025 results, including a 25.6% revenue increase to £105.6 million and narrowed adjusted EBITDA losses of £48.3 million, which beat analyst expectations for underlying loss. The molecular sensing specialist achieved broad-based growth across all regions and customer segments, reaffirming its full-year guidance for 20-23% constant currency revenue growth and medium-term targets, including adjusted EBITDA breakeven by FY27. The stock's counterintuitive decline, despite robust operational performance and a stable outlook, suggests a potential disconnect with market sentiment or elevated investor expectations.

Analysis

Oxford Nanopore Technologies (LSE:ONT) reported a strong first half for 2025, with revenue climbing 25.6% to £105.6 million while significantly narrowing its adjusted EBITDA loss to £48.3 million from £61.7 million a year prior, beating average City forecasts. This performance was underpinned by broad-based expansion across all geographies, led by APAC (+38.3%), and all customer segments, with the Clinical market showing exceptional growth of 52.9%. A notable shift in product mix is evident, as sales of the high-output PromethION platform surged 59.6%, offsetting a minor 3.1% decline in the smaller MinION platform. Despite these robust operational results, the stock declined 2.9%, indicating a potential disconnect between the company's fundamental performance and current market sentiment. The company's stable outlook is supported by its reaffirmation of full-year guidance (20-23% revenue growth) and medium-term targets, including adjusted EBITDA breakeven by FY27, which appears well-funded by a cash and liquid investments position of £337.3 million. The paradoxical share price movement suggests investors may be focused on the upcoming CEO transition or weighing the small decline in MinION sales more heavily than the overall positive results.

Key Decisions for Investors

• Investors may view the 2.9% share price decline, in contrast to strong revenue growth and a loss beat, as a potential entry point if they believe the fundamental growth trajectory remains intact.
• It is critical to monitor the sales trajectory of the high-output PromethION platform, as its continued 59.6% growth is key to driving future profitability and validating the company's up-market strategy.
• Close attention should be paid to the upcoming CEO transition, as any deviation from the reaffirmed strategy for achieving EBITDA breakeven by FY27 could introduce significant risk to the medium-term investment case.